Angle-Supported Phakic IOL for Myopia: 4-Year Results

Saturday, April 18, 2015: 4:06 PM
Room 4 (San Diego Convention Center)
Ruth Lapid-Gortzak, MD, PhD
Ivanka J. Van Der Meulen, MD PhD
Jan Willem Van Der Linden, BOptom, FAAO
Violette Vrijman

To report the results of implantation of an angle supported phakic anterior chamber IOL (pIOL)  for myopia.

Prospectively gathered data on 59 eyes (31 patients) implanted with a pIOL (Acrysof Cachet, Alcon, USA) for a mean myopia of -9.48+2.83 was analyzed. Outcome measures were visual and refractive parameters, endothelial cell count, as well as pIOL rotation during follow up.

Postoperatively at 6 months 77% were within 0.5 D of emmetropia, and 89% were within 1 D of emmetropia. Mean postoperative uncorrected distance visual acuity (UDVA) was logMAR 0.02+-0.14, and the mean spherical equivalent (SE) was -0.29 D+0.42. Rotation was seen in 46% of eyes, and of these 44% showed further rotation after the initial rotation documented. This was not correlated to Endothelial cell count, or biometric data.

The pIOL gives excellent results in terms of UVDA and refraction, with a good safety profile within the first few years after implantation. In 46% pIOL rotation was detected initially, which was not related to endothelial cell counts. The long-term safety still remains to be proven.